ROSWELL, Ga., Feb. 25, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) granted approval of MIUDELLA® ...
To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world through an online application process, paying special attention to growing fields—such as ...
Dr Attila Vereczkey discusses intrauterine adhesions and recent advancements in their prevention, including regenerative therapies ...
BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study.
August 26, 2010 — For women with documented idiopathic heavy menstrual bleeding, the levonorgestrel-releasing intrauterine system is associated with a greater reduction in menstrual blood loss and a ...
Women who use copper intrauterine devices (IUD) as a form of birth control may be at lower risk for high-grade cervical cancer compared with those who use a levonorgestrel-releasing intrauterine ...
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Mirena (levonorgestrel-releasing intrauterine system; Bayer), to extend the indication to up to 6 ...
Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...
Low-dose levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg and 19.5 mg is associated with a significantly lower risk of first-time depression vs high dose LNG-IUS 52 mg. Overall, 46,565 ...
About The Study: This Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results